WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…
SHERIDAN, WY , Aug. 26, 2025 (GLOBE NEWSWIRE) -- As consumers seek science-informed, non-pharmacological options for chronic pain and recovery,…
Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin…
CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total…
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…